SCHEMBL16239183

SCHEMBL16239183

CC(C)(C)OC(=O)NCc1ccc(Nc2ccc3ccccc3c2N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.49
BRD4 O60885 1/20 0.48
HDAC1 Q13547 3/20 0.46
KDM4A O75164 1/20 0.44
NQO2 P16083 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA1 P00915 2/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
CA2 P00918 1/20 0.40
NCEH1 Q6PIU2 1/20 0.40
GAA P10253 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
IGF1R P08069 1/20 0.39
CA12 O43570 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29908796 1.00 NAMPT (0.49) NAMPTBRD4HDAC1KDM4ANQO2
SCHEMBL29908838 0.86 BRD4 (0.43) NAMPTBRD4NCEH1GAA
SCHEMBL15091057 0.86 BRD4 (0.43) NAMPTBRD4NCEH1GAA
SCHEMBL16239229 0.83 NAMPT (0.46) NAMPTBRD4HDAC1KDM4ANQO2
SCHEMBL16238914 0.82 TSHR (0.47) NCEH1CYP1A2CYP2D6
SCHEMBL29908813 0.79 BCHE (0.49) BRD4KDM4ANQO2CA1CA2
SCHEMBL15090993 0.79 BRD4 (0.46) BRD4HDAC1MAPTHDAC10HDAC6
SCHEMBL29908816 0.78 KMT2A (0.43) GAA
SCHEMBL16239142 0.78 KMT2A (0.43) GAA
SCHEMBL2807761 0.75 NAMPT (0.51) NAMPTBRD4HDAC1KDM4AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2022-12-01 US disclosed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380322-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3485/4885BRD4 416/4885HDAC1 2936/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3266/4885BRD4 421/4885HDAC1 2964/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 NAMPT 3338/4885BRD4 418/4885HDAC1 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.